3SBio Signs Deal For Isotechnika's Transplant/Immune System Drug Voclosporin
This article was originally published in The Pink Sheet Daily
Executive Summary
The deal was announced less than three weeks after U.S. FDA requested an additional Phase III trial for an oral voclosporin used in uveitis therapy.
You may also be interested in...
Last-Minute Cancellation Of Advisory Panel Meeting Throws Future of Luveniq Into Doubt
"Several outstanding issues" forced FDA to cancel the meeting, the agency said.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.